Dublin-listed pharmaceutical services company Open Orphan said it has developed the world’s first challenge study model to test the efficacy of the large number of potential Covid-19 vaccines.
Challenge study models involve patients that are deliberately exposed to a disease – in this case to a form of the virus.
The company recently signed what it described as a “major” deal with an unnamed vaccine developer through its Venn Life Sciences unit.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).